# Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer

> **NCT00077376** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 61 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Male Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** ixabepilone
- **DRUG:** carboplatin
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00077376
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2009-03
- **Final completion:** 2011-03
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2014-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077376, "Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00077376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*